1. ZHAW digitalcollection
  2. School of Engineering
  3. Publikationen
  4. Publikationen School of Engineering
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-25988
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCueni, Claudia-
dc.contributor.authorNytko, Katarzyna J.-
dc.contributor.authorThumser-Henner, Pauline-
dc.contributor.authorWeyland, Mathias S.-
dc.contributor.authorRohrer Bley, Carla-
dc.date.accessioned2022-11-10T10:37:05Z-
dc.date.available2022-11-10T10:37:05Z-
dc.date.issued2020-
dc.identifier.issn2053-1095de_CH
dc.identifier.issn2053-1095de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/25988-
dc.description.abstractOpioid receptor activation was shown to enhance the efficacy of anti-neoplastic drugs in several human cancer cell lines. In these cell lines, doxorubicin increased the number of opioid receptors and methadone concurrently enhanced cellular doxorubicin uptake. Triggered through lay press and media, animal owners started to challenge veterinary oncologists with questions about methadone use in anti-cancer therapy. Especially in veterinary medicine, where side effects of chemotherapy are tolerated to a lesser extent and hence smaller doses are given, agents potentiating chemotherapeutic agents would be an optimal approach to treatment. Canine transitional cell carcinoma cells (TCC, K9TCC), canine osteosarcoma cells (OSA, Abrams) and canine hemangiosarcoma cells (HSA, DAL-4) were incubated with different combinations of methadone, buprenorphine and doxorubicin, in order to test inhibition of cell proliferation. Opioid receptor density was assessed with fluorescence-activated cell sorting in drug native and doxorubicin pretreated cells. In TCC and OSA cell lines opioid receptor density increased after doxorubicin pretreatment. In combination treatment, however, we did not find significant potentiation of doxorubicin's inhibitory effect on proliferation in these cell lines. Neither was there a significant increase of the effect of doxorubicin when the opioids were added 24 hr before doxorubicin. Hence, we could not confirm the hypothesis that opioids increase the anti-proliferative effect of the anti-neoplastic drug doxorubicin in any of these canine tumour cell lines. The lack of effect on a cellular level does not warrant a clinical approach to use opioids together with doxorubicin in dogs with cancer.de_CH
dc.language.isoende_CH
dc.publisherWileyde_CH
dc.relation.ispartofVeterinary Medicine and Sciencede_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectBuprenorphinede_CH
dc.subjectCancerde_CH
dc.subjectDogde_CH
dc.subjectFlow cytometryde_CH
dc.subjectOpioid receptorde_CH
dc.subjectµ-receptorde_CH
dc.subjectAnimalde_CH
dc.subjectAntineoplastic agentde_CH
dc.subjectBuprenorphinede_CH
dc.subjectCell line, tumorde_CH
dc.subjectCell proliferationde_CH
dc.subjectDoxorubicinde_CH
dc.subjectMethadonede_CH
dc.subject.ddc630: Landwirtschaftde_CH
dc.titleMethadone does not potentiate the effect of doxorubicin in canine tumour cell linesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Engineeringde_CH
zhaw.organisationalunitInstitut für Angewandte Mathematik und Physik (IAMP)de_CH
dc.identifier.doi10.1002/vms3.266de_CH
dc.identifier.doi10.21256/zhaw-25988-
dc.identifier.pmid32306524de_CH
zhaw.funding.euNode_CH
zhaw.issue3de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end289de_CH
zhaw.pages.start283de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume6de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Engineering

Files in This Item:
File Description SizeFormat 
2020_Cueni-etal_Methadone-does-not-potentiate-the-effect-of-doxorubicin_Vet-Med-Sci.pdf589.89 kBAdobe PDFThumbnail
View/Open
Show simple item record
Cueni, C., Nytko, K. J., Thumser-Henner, P., Weyland, M. S., & Rohrer Bley, C. (2020). Methadone does not potentiate the effect of doxorubicin in canine tumour cell lines. Veterinary Medicine and Science, 6(3), 283–289. https://doi.org/10.1002/vms3.266
Cueni, C. et al. (2020) ‘Methadone does not potentiate the effect of doxorubicin in canine tumour cell lines’, Veterinary Medicine and Science, 6(3), pp. 283–289. Available at: https://doi.org/10.1002/vms3.266.
C. Cueni, K. J. Nytko, P. Thumser-Henner, M. S. Weyland, and C. Rohrer Bley, “Methadone does not potentiate the effect of doxorubicin in canine tumour cell lines,” Veterinary Medicine and Science, vol. 6, no. 3, pp. 283–289, 2020, doi: 10.1002/vms3.266.
CUENI, Claudia, Katarzyna J. NYTKO, Pauline THUMSER-HENNER, Mathias S. WEYLAND und Carla ROHRER BLEY, 2020. Methadone does not potentiate the effect of doxorubicin in canine tumour cell lines. Veterinary Medicine and Science. 2020. Bd. 6, Nr. 3, S. 283–289. DOI 10.1002/vms3.266
Cueni, Claudia, Katarzyna J. Nytko, Pauline Thumser-Henner, Mathias S. Weyland, and Carla Rohrer Bley. 2020. “Methadone Does Not Potentiate the Effect of Doxorubicin in Canine Tumour Cell Lines.” Veterinary Medicine and Science 6 (3): 283–89. https://doi.org/10.1002/vms3.266.
Cueni, Claudia, et al. “Methadone Does Not Potentiate the Effect of Doxorubicin in Canine Tumour Cell Lines.” Veterinary Medicine and Science, vol. 6, no. 3, 2020, pp. 283–89, https://doi.org/10.1002/vms3.266.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.